Back to News
Market Impact: 0.2
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Source: globenewswire.com
Healthcare & BiotechCompany FundamentalsProduct Launches
ATTO-1310 showed preliminary clinical proof-of-concept in chronic pruritus and high-itch atopic dermatitis (AD), supporting the program’s early efficacy signal. The company expects complete Phase 1b data in Q4 2026, extending the timeline for catalysts and keeping near-term upside modest.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- India's large caps stuck in 'bygone economic era', says Bernstein, as foreign investors head for the exit
- Novo CEO signals M&A opportunities to strengthen drug pipeline
- Alibaba shares jump as new AI chip, data center buildout plans unveiled
- Steve Jobs made Apple iconic. Tim Cook made it a $5 trillion behemoth
- Alibaba Cloud plans six-year stroll to 20GW of datacenters, reveals chip to power them
- Australia’s IDP rejects Blackstone’s $494 million takeover offer